{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:25:59Z","timestamp":1787765159549,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim of Study:<\/jats:title>\n                    <jats:p>To study the clinico-epidemiological profile and identify risk factors for the development of COVID-19-associated mucormycosis (CAM) among the patients treated at our regional mucormycosis center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a cross-sectional single-centre observational study. All CAM patients admitted to Government Rajaji Hospital, Madurai from April 2021- August 2021 were included in the study. Information regarding clinical features, potential risk factors, diagnostic workup, and comorbid illness was collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 164 patients of CAM were admitted to our hospital with a mean age of 51.7 years. Out of 164 patients, 12 patients were not covid positive, based on imaging and RT-PCR, however subclinical infection could not be ruled out. Out of the 164 patients studied, 160 patients had diabetes, out of which 66% (n = 105) patients had a previous history of diabetes, and 34% (n = 55) had newly detected diabetes. Most of the patients admitted with mucormycosis had uncontrolled diabetes (94%) and were not on insulin therapy, but were on oral antidiabetic drugs alone. The majority of the patients (68%) have received steroids (IV\/oral) during the COVID-19 illness. 74% of these patients were under hospitalization for COVID-19 disease. Only 30% (n = 50) of CAM patients had a history of oxygen therapy and 7% of these patients were treated in ICU during active COVID-19 illness. 59% of patients used cloth masks without adequate hygiene, rest 41% (n = 67) patients reused disposable masks. We also found that 87% of the patients developing mucormycosis had exposure to organic material in the convalescence period of COVID-19 illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>From our study, we found steroid use, poorly controlled diabetes mellitus, reuse of masks, daily steam inhalation, and exposure to organic matter to be more associated with CAM, but oxygen therapy was less associated with CAM. Hence, we could suggest screening for hyperglycemia and daily use of disposable surgical masks to be continued for at least 4 weeks post-COVID-19. It is preferable to continue insulin in titrated doses along with OHA for at least 4 weeks following steroid cessation in the post-COVID-19 period as there is are considerably increased inflammatory cytokine levels in the convalescence phase. Clean environmental hygiene would also help prevent CAM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_372_22","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T05:00:56Z","timestamp":1705035656000},"page":"519-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology, Clinical Profile, and Analysis of Risk Factors in COVID Associated Rhino-orbito-cerebral Mucormycosis Patients - An Observational Study"],"prefix":"10.4103","volume":"27","author":[{"given":"Komal","family":"Jog","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetology, Madurai Medical College and Govt. Rajaji Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Nazirudeen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, Madurai Medical College and Govt. Rajaji Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbiah","family":"Eagappan","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Madurai Medical College and Govt. Rajaji Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavan K.","family":"Santharam","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, Madurai Medical College, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbiah","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Madurai Medical College and Govt. Rajaji Hospital, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41479-021-00083-w","article-title":"The role of co-infections and secondary infections in patients with COVID-19","volume":"13","author":"Feldman","year":"2021","journal-title":"Pneumonia"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2213-2600(21)00265-4","article-title":"Rising incidence of mucormycosis in patients with COVID-19:Another challenge for India amidst the second wave?","volume":"9","author":"Raut","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis:An update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/microorganisms9030523","article-title":"Epidemiology of mucormycosis in India","volume":"9","author":"Prakash","year":"2021","journal-title":"Microorganisms"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"e00433","DOI":"10.1128\/JCM.00433-18","article-title":"Emerging Rhizopus microsporus Infections in India","volume":"56","author":"Pandey","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11046-020-00462-9","article-title":"Fungal Co-infections associated with global COVID-19 pandemic:A clinical and diagnostic perspective from China","volume":"185","author":"Song","year":"2020","journal-title":"Mycopathologia"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/myc.13096","article-title":"COVID-19 associated pulmonary aspergillosis","volume":"63","author":"Koehler","year":"2020","journal-title":"Mycoses"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/jof7040298","article-title":"When uncontrolled diabetes mellitus and severe COVID-19 converge:The perfect storm for mucormycosis","volume":"7","author":"John","year":"2021","journal-title":"J Fungi"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"944.e9","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"(Suppl_1)","key":"R11-20240828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ofid\/ofv133.336","article-title":"Determining the incubation time of mucormycosis:A systematic review","volume":"2","author":"Smith","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"108142","DOI":"10.1016\/j.diabres.2020.108142","article-title":"COVID-19 and diabetes:Knowledge in progress","volume":"162","author":"Hussain","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/dom.14098","article-title":"Why is hyperglycaemia worsening COVID-19 and its prognosis?","volume":"22","author":"Ceriello","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/myc.12243","article-title":"Mucormycosis in India:Unique features","volume":"57","author":"Chakrabarti","year":"2014","journal-title":"Mycoses"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2213-2600(20)30530-0","article-title":"Corticosteroids for COVID-19:The search for an optimum duration of therapy","volume":"9","author":"Mishra","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/myc.13256","article-title":"The double-edged sword of systemic corticosteroid therapy in viral pneumonia:A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis","volume":"64","author":"Ahmadikia","year":"2021","journal-title":"Mycoses"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-021-01397-4","article-title":"SARS-CoV-2 variants of concern are emerging in India","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_372_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:01:41Z","timestamp":1787763701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_372_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_372_22","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"2022-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}